key: cord-0920813-srj99q43 authors: Rosenbloom, Daniel Scholes; Zhao, Ping; Sinha, Vikram title: Initiation of Antiviral Treatment in SARS‐CoV2: Modeling Viral Dynamics and Drug Properties date: 2020-07-22 journal: CPT Pharmacometrics Syst Pharmacol DOI: 10.1002/psp4.12550 sha: de3f8b76ebceaa26d9f234048466b62149a91811 doc_id: 920813 cord_uid: srj99q43 As the coronavirus disease (COVID‐19) pandemic has evolved, the search for vaccines and treatments continues in earnest. This pandemic is causing sharp increases in morbidity and mortality and an urgency to make therapies widely available. The COVID‐19 pandemic reveals the limited preparedness of health systems worldwide, and health care workers have very few options to combat this emergent disease and save patients’ lives. As the coronavirus disease (COVID-19) pandemic has evolved, the search for vaccines and treatments 2 continues in earnest. This pandemic is causing sharp increases in morbidity and mortality and an urgency 3 to make therapies widely available. The COVID-19 pandemic reveals the limited preparedness of health 4 systems worldwide, and health care workers have very few options to combat this emergent disease and 5 save patients' lives. This search for new vaccines and treatments is a test of our collective ability to 6 assess medications, presenting both an opportunity and a challenge to drug research, development, and 7 approval apparatus. Well-conducted randomized, controlled trials in acutely ill patients will be needed to 8 evaluate survival, hospitalization, number of days spent in intensive care, and need for a ventilator. Current strategies generally employ one of two approaches: novel treatments targeted against the virus 10 and re-purposed drugs with well characterized clinical safety and pharmacokinetics. Prior to large clinical trials, assessing the therapeutic potential of repurposed drugs based only on very 12 early efficacy data -including in vitro studies or preliminary clinical experiences -is a major challenge 1,2 . Quantitative modeling and simulation approaches can tackle this challenge by integrating the available 14 data to provide optimal dosing recommendations, either within a clinical trial or in an emergency setting. However, if treatment does not start until symptoms emerge, then 90% efficacy would be required for the 27 same outcome. Conceptually, their work is illustrated in Figure 1 . In their assessment, a treatment that 28 reduces peak viral load 100-fold is assumed to achieve desired clinical outcomes. Both the potency and 29 timing of treatment determine outcomes (red and light blue curves). The basic model fits the data well and This article is protected by copyright. All rights reserved Accepted Article The Approved Dose of Ivermectin Alone is 83 not the Ideal Dose for the Treatment of COVID-19 Connecting 87 hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral 88 effect: a critical step in treating COVID-19 patients Timing 92 of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load Accepted Author Manuscript Combination Antiviral Therapy for Influenza: 329 95 Predictions from Modeling of Human Infections Kinetics of 97 influenza A virus infection in humans Host Response to SARS-CoV-2 Drives Development of COVID-19 Past HBV viral load as predictor 102 of mortality and morbidity from HCC and chronic liver disease in a prospective study Clinical 105 correlation of influenza and respiratory syncytial virus load measured by digital PCR Joint Modeling of the Clinical Progression 108 and of the Biomarkers' Dynamics Using a Mechanistic Model Joint Models for Longitudinal and Time-to-Event Data: With Applications 111 in R Post-treatment control of HIV infection Mathematical Analysis of Viral Replication Dynamics and Antiviral 116 Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling Treatment with 119 integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a 120 subset of cells with slow integration